Name: UMIN ID:
Unique ID issued by UMIN | UMIN000001331 |
---|---|
Receipt number | R000001613 |
Scientific Title | Phase II study of neoadjuvant Letrozole combined with low dose metronomic Cyclophosphamide for postmenopausal women with Endocrine-responsive Breast Cancer (JBCRG-07) |
Date of disclosure of the study information | 2008/08/22 |
Last modified on | 2021/08/18 09:41:00 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2008/08/21 23:33:44 | ||
2 | Update | 2008/12/16 14:27:15 | Email1 |
|
3 | Update | 2009/08/21 11:19:37 | Organization Organization Institute Organization Organization1 |
|
4 | Update | 2009/10/29 19:55:07 | Recruitment status |
|
5 | Update | 2011/02/21 11:45:24 | Recruitment status |
|
6 | Update | 2011/08/31 14:19:14 | Post marketing survey by drug manufacture etc., specified by Japanese law. Tel1 |
|
7 | Update | 2011/11/15 15:50:40 | Publication of results Other related information Other related information |
|
8 | Update | 2014/02/21 13:52:43 | Email Institutions |
|
9 | Update | 2014/08/26 09:27:11 | Address Address TEL Address Address TEL Address1 Tel1 |
|
10 | Update | 2014/09/26 10:23:40 | Last follow-up date |
|
11 | Update | 2015/08/24 10:42:25 | Recruitment status |
|
12 | Update | 2016/07/06 09:38:20 | Name of primary person or sponsor Organization |
|
13 | Update | 2018/08/24 10:02:54 | UMIN ID1 UMIN ID2 |
|
14 | Update | 2019/11/21 16:47:57 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Organization Zip code Address Homepage URL Organization Institute Organization Organization1 Organization Organization Address Address Tel |
|
15 | Update | 2019/11/21 16:52:26 | Date of IRB Anticipated trial start date |
|
16 | Update | 2021/08/18 09:41:00 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |